Developing
Bispecific Antibodies
that exploit the therapeutic potential of the natural immune system.
SITC 2025 POSTER PRESENTATION
Click on thumbnail to download the pdf
Reverb's Bispecific Antibody Platform Amplifies Natural Cytokine Signaling
Key Advantages
Contact us to know more about Amplify·R
Our Team
You may click on each picture to read their biography.
David De Graaf, PhD
Founder and Chief Executive Officer
Surjit Dixit, PhD
Founder and Chief Scientific Officer
Diana Hausman, MD
Chief Medical Officer *
​
Jean M. Jen, CPA, CA
Chief Financial Officer *​
​
John M. Burke, PhD
Chief Pharmacology Officer *
Jennifer Kaufman-Shaw, JD, PhD
Strategic IP Advisor​​
Stacey Tom-Yew, PhD
Protein Engineering & Sciences​​
Anthony Walsh, PhD
Strategic Advisor
Mark Fogg, PhD
Vice President, Immunology​
Harsh Pratap, MS
Immunology​
Ahmed Alkhateeb, PhD
Chief Business Officer *​
Abhishek Mukhopadhyay, PhD
Computational Biology​
Vivian Z. Li, BBioTech
Immunology​
* Fractional
Our Board of Directors
You may click on each Board member's name to read their biography.
Board Chair
Founder and Partner
Amplitude
Director, Founder and CEO
Reverb Therapeutics
​
Independent Board Director
​
​
Director, Founder
and Principal,
Amplitude
Independent Board Director
​
​
Board Advisor
​
​
Reverb Development Pipeline
Our Investors
You may click on any logo to access our investors' websites.
AMPLITUDE VC
KDT VENTURES
MYELOMA INVESTMENT FUND
FINCHLEY HEALTHCARE VENTURES
SEIDO CAPITAL
inBC INVESTMENT